Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
Elizabeth Smyth MD
Elizabeth Smyth MD Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · September 15, 2016

Tolerability of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer

Clinical Colorectal Cancer

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Clinical Colorectal Cancer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the PAVES Study
Clin Colorectal Cancer 2016 Sep 07;[EPub Ahead of Print], T Pinter, Z Klippel, A Cesas, A Croitoru, J Decaestecker, P Gibbs, Y Hotko, J Jassem, G Kurteva, J Novotny, S O’Reilly, T Salek, M Reiner, PK Morrow, MR Choi, S Whittaker, C Blanke

Further Reading

Most Read This Week

Recently Updated